mRNA Therapeutics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 18.8 billion
Estimated Base Value
2035 Forecast
US$ 62.7 billion
Projected Market Value
CAGR 2026–2035
12.8%
Compound Annual Growth
Largest Segment
Prophylactic mRNA Vaccines
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
BioNTech
Emerging Players
Laronde, ReNAgade Therapeutics
mRNA Therapeutics Market Overview
The mRNA Therapeutics Market encompasses medicinal products that utilize messenger RNA to direct the body's cells to produce specific proteins. These proteins can elicit an immune response against pathogens, substitute deficient proteins, or target diseased cells, offering preventive or therapeutic solutions for a broad spectrum of conditions. This market is a key area within precision therapeutics, concentrating on innovative mRNA-based vaccines and therapeutic drugs across various indications. Key buyers include pharmaceutical and biotechnology companies, academic and research institutes, and healthcare providers such as hospitals and specialty clinics, all seeking advanced solutions for disease management and prevention.
The mRNA Therapeutics Market is estimated at $18.8 Bn in 2025 and is forecast to reach $62.7 Bn in 2035, growing at a CAGR of 12.8% from 2025 to 2035. Demand is driven by the demonstrated efficacy of mRNA vaccines, the increasing prevalence of chronic and infectious diseases, and substantial R&D investment. Factors restraining market growth include high manufacturing costs, complex cold chain logistics, challenges related to mRNA instability and efficient delivery, and the potential for unwanted immunogenicity, which can impact broader adoption and market expansion.
The market is segmented by Type (Prophylactic Mrna Vaccines, Therapeutic Mrna Vaccines, Mrna Therapies for Protein Replacement, Mrna Therapies for Gene Editing, Mrna Therapies for Regenerative Medicine, Mrna Immunomodulators), Technology (Lipid Nanoparticle Delivery, Polymeric Nanoparticle Delivery, Self-Amplifying Mrna, Non-Amplifying Mrna, Circular Mrna, Chemically Modified Mrna), Application (Infectious Diseases, Oncology, Genetic Disorders, Autoimmune Diseases, Cardiovascular Diseases, Metabolic Diseases, Rare Diseases, Others), End-User (Hospitals, Specialty Clinics, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Government Agencies), Component (Mrna Active Pharmaceutical Ingredients, Lipid Nanoparticle Components, Plasmid DNA, Enzymes & Reagents, Buffers & Excipients, Analytical & Purification Equipment, Formulation & Fill-Finish Equipment, Others), and Process (Plasmid DNA Manufacturing, In Vitro Transcription, Mrna Purification, Lipid Nanoparticle Formulation, Aseptic Fill & Finish, Quality Control & Assurance, Downstream Processing). It is served across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include BioNTech, CureVac, Arcturus Therapeutics, Gritstone Bio, Orna Therapeutics, Strand Therapeutics, Ethris GmbH, eTheRNA immunotherapies, Nutcracker Therapeutics, ReCode Therapeutics, Ziphius Vaccines, and Sana Biotechnology. The full report provides a comprehensive analysis of these segments, regional dynamics, competitive landscape, and market outlook.
Market Definition & Overview
The mRNA Therapeutics Market involves the development, manufacturing, and commercialization of medicinal products that leverage messenger RNA (mRNA) to instruct the body's cells to produce specific proteins. These proteins can stimulate an immune response against pathogens, replace deficient proteins, or target diseased cells, thereby preventing or treating a wide range of conditions. This market, a key segment of precision therapeutics, focuses on innovative mRNA-based vaccines and therapeutic drugs across various indications, driving significant advancements in personalized medicine and rapid response to global health challenges.
Scope
- Global market analysis across major continents and countries
- Segmentation by application (infectious diseases, oncology, rare diseases)
- Segmentation by product type (prophylactic vaccines, therapeutic drugs)
- Forecast period typically covers 2025 to 2035, with historical data from 2020
Inclusions
- mRNA-based prophylactic vaccines for infectious diseases
- mRNA therapeutic drugs for oncology (e.g., cancer vaccines)
- mRNA therapies for rare genetic disorders and protein replacement
- mRNA vaccines and therapeutics for autoimmune diseases
- Lipid nanoparticle (LNP) and other delivery systems designed for mRNA
- Contract manufacturing and development services for mRNA products
Exclusions
- Traditional protein-based biologics and small molecule drugs
- DNA-based gene therapies and gene editing technologies (e.g., CRISPR)
- Cellular therapies not primarily utilizing mRNA modification
- Research reagents and tools not directly part of a therapeutic product
- Diagnostic products and kits unrelated to mRNA therapeutic development
- Veterinary or animal health applications of mRNA technology
Market Size Forecast
Executive Summary
• The mRNA Therapeutics market is valued at $18.8 Bn in 2025 and is forecast to reach $62.7 Bn by 2035, reflecting a robust CAGR of 12.8% as demand accelerates across every major segment and region over the ten-year outlook.
• Prophylactic mRNA Vaccines leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Therapeutic diversification beyond infectious diseases into oncology and autoimmune conditions, propelled by advanced delivery technologies, will drive the mRNA market's next growth phase, reshaping precision medicine paradigms globally.
• Intensifying competition from Big Pharma’s strategic investments and a surge in biotech innovation are fostering a dynamic, yet consolidating, market landscape, necessitating agile partnership and M&A strategies.
• Evolving regulatory frameworks and breakthroughs in mRNA stability and targeted delivery mechanisms are accelerating clinical pipelines, enabling novel applications across previously intractable conditions and streamlining global approvals.
• Scaling specialized manufacturing capabilities and ensuring resilient global supply chains are critical imperatives, directly influencing market access, cost-effectiveness, and regional therapeutic availability across all key segments.
• Sustained venture capital and strategic partnerships are funneling significant investment into next-generation mRNA platforms, particularly in personalized medicine and emerging therapeutic areas, signaling robust long-term potential.
• While developed markets lead in adoption, targeted investments in emerging economies and expanded indications will drive new growth pockets, demanding localized clinical development and market entry strategies.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Valuation
The mRNA Therapeutics Market was valued at an substantial $18.8 billion in the base year, establishing its significant industry presence.
Future Market Expansion
This market is projected to achieve a valuation of $62.7 billion by the forecast year, underscoring its immense growth potential.
Robust Growth Outlook
The market is set for exceptional expansion, exhibiting a Compound Annual Growth Rate (CAGR) of 12.8% from the base year to the forecast year.
Infectious Disease Leadership
The infectious diseases segment, notably driven by successful vaccine developments, is expected to remain a primary contributor to market revenue.
Pipeline Diversification
A key trend is the increasing diversification of mRNA therapeutic pipelines, expanding beyond vaccines into oncology, rare diseases, and gene editing applications.
Innovation and Investment
Continuous technological innovation and substantial investments from both private and public sectors are accelerating the development and commercialization of new mRNA therapies.
Market Dynamics
Market Trends
- Focus on oncology applications is expanding beyond infectious diseases.
- Increased collaboration between biotech firms and large pharmaceutical companies.
- Automation and AI are streamlining mRNA drug discovery and manufacturing.
- Advancements in lipid nanoparticle (LNP) delivery systems continue to emerge.
Growth Drivers
- High efficacy demonstrated by COVID-19 mRNA vaccines.
- Growing prevalence of chronic and infectious diseases globally.
- Significant R&D investment and government funding for mRNA research.
- Faster development timelines compared to traditional drug platforms.
Restraints
- High manufacturing costs and complex cold chain logistics challenge accessibility.
- mRNA instability and efficient delivery to target cells remain significant hurdles.
- Potential for unwanted immunogenicity raises safety concerns for repeated dosing.
- Navigating complex regulatory pathways can impede rapid market approval and adoption.
Opportunities
- Developing mRNA therapies for rare genetic diseases.
- Expanding applications into autoimmune disorders and cardiovascular diseases.
- Personalized cancer vaccines leveraging advanced mRNA technology.
- Enhanced delivery systems for broader tissue targeting and reduced side effects.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Prophylactic Mrna VaccinesTherapeutic Mrna VaccinesMrna Therapies for Protein ReplacementMrna Therapies for Gene EditingMrna Therapies for Regenerative MedicineMrna Immunomodulators |
| By Technology | Lipid Nanoparticle DeliveryPolymeric Nanoparticle DeliverySelf-Amplifying MrnaNon-Amplifying MrnaCircular MrnaChemically Modified Mrna |
| By Application | Infectious DiseasesOncologyGenetic DisordersAutoimmune DiseasesCardiovascular DiseasesMetabolic DiseasesRare DiseasesOthers |
| By End-User | HospitalsSpecialty ClinicsAcademic & Research InstitutesPharmaceutical & Biotechnology CompaniesContract Research OrganizationsGovernment Agencies |
| By Component | Mrna Active Pharmaceutical IngredientsLipid Nanoparticle ComponentsPlasmid DNAEnzymes & ReagentsBuffers & ExcipientsAnalytical & Purification EquipmentFormulation & Fill-Finish EquipmentOthers |
| By Process | Plasmid DNA ManufacturingIn Vitro TranscriptionMrna PurificationLipid Nanoparticle FormulationAseptic Fill & FinishQuality Control & AssuranceDownstream Processing |
Regional Analysis
- North America leads the mRNA therapeutics market due to substantial R&D investments, a robust ecosystem of pharmaceutical companies, and favorable regulatory support. High healthcare expenditure and significant venture capital funding further solidify its dominance in developing and commercializing innovative treatments.
- The Asia-Pacific region is emerging as the fastest-growing market, driven by increasing government support for biotechnology and expanding research infrastructure. Rising healthcare expenditure and a large, aging population needing advanced therapies are significant growth catalysts.
- Europe is increasingly focusing on building robust domestic mRNA manufacturing capabilities and fostering cross-border research collaborations. This aims to enhance supply chain resilience and accelerate novel therapeutic development, particularly post-pandemic.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- North America leads the market due to robust R&D infrastructure, significant investment in biotechnology, and the presence of major pharmaceutical companies driving innovation and product development.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Latin America represents a growing market, with increasing awareness and adoption of advanced therapeutics, alongside efforts to improve healthcare infrastructure and access to innovative treatments.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Europe holds a strong market position, supported by advanced healthcare systems, substantial public and private funding for research, and a growing number of clinical trials in mRNA therapeutics.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- The Asia Pacific region is experiencing rapid growth, driven by increasing healthcare expenditure, a large patient pool, and rising investments in biopharmaceutical R&D, particularly in countries like China, Japan, and India.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- The Middle East & Africa region shows significant growth potential from a lower base, fueled by government initiatives to diversify economies and invest in healthcare innovation, coupled with a rising demand for specialized therapies.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The global leader in mRNA therapeutics R&D, manufacturing, and commercialization, driven by substantial public and private investment, a robust biotech ecosystem, and early regulatory approval pathways. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | The largest market in South America with significant healthcare needs and a vast population, driving demand for innovative vaccines and therapies, alongside growing domestic R&D interest and public health initiatives. |
| 3 | Germany | US$ XX.X Mn | XX.X% | A pioneer in mRNA technology, boasting leading research institutions and key companies like BioNTech, driving significant R&D, manufacturing, and clinical trials for new mRNA therapeutics. |
| 4 | China | US$ XX.X Mn | XX.X% | A rapidly growing market with massive investment in biotech, extensive R&D capabilities, and a large population, positioning it as a major force in the development and adoption of mRNA therapeutics through domestic innovation. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | A key emerging market in the Middle East, with substantial government investment in healthcare infrastructure and biotech R&D as part of Vision 2030, aiming for self-sufficiency in advanced therapies and regional leadership. |
Countries Covered (27)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Italy, Spain, Russia, Rest of Europe, China, Japan, South Korea, India, Australia, Taiwan, Malaysia, Rest of Asia Pacific, Saudi Arabia, Israel, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | BioNTech | XX.X% | Leverage deep mRNA expertise and strategic partnerships to develop a broad portfolio of individualized immunotherapies and infectious disease vaccines. | — | — | ComirnatyBNT111BNT122+1 |
| 2 | CureVac | XX.X% | Focus on the development of a new generation of mRNA vaccines and therapeutics utilizing its proprietary modified mRNA technology platform. | — | — | CV2705CV2502CV0501 |
| 3 | Arcturus Therapeutics | XX.X% | Utilize its self-amplifying mRNA (sa-mRNA) technology and LUNAR lipid nanoparticle delivery platform to develop vaccines and therapies for infectious diseases and rare genetic disorders. | — | — | ARCT-154ARCT-810ARCT-032 |
| 4 | Gritstone Bio | XX.X% | Develop personalized and off-the-shelf cancer immunotherapies using a unique self-amplifying mRNA approach combined with neoantigen identification. | — | — | GRANITESLATEGRT-R914 |
| 5 | Orna Therapeutics | XX.X% | Pioneer the development of circular RNA (oRNA) therapeutics, which offer potentially enhanced stability and protein production compared to linear mRNA. | — | — | oRNA-based cancer therapiesoRNA-based autoimmune therapies |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
BioNTech, CureVac, Arcturus Therapeutics, Gritstone Bio, Orna Therapeutics, Strand Therapeutics, Ethris GmbH, eTheRNA immunotherapies, Nutcracker Therapeutics, ReCode Therapeutics, Ziphius Vaccines, Sana Biotechnology, Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Omega Therapeutics, Entos Pharmaceuticals, Arbutus Biopharma, Acuitas Therapeutics, Evox Therapeutics
The global mRNA Therapeutics market features a competitive landscape led by BioNTech, CureVac, Arcturus Therapeutics, Gritstone Bio, Orna Therapeutics, and Strand Therapeutics, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
BioNTech
CureVac
Arcturus Therapeutics
Gritstone Bio
Orna Therapeutics
Strand Therapeutics
Ethris GmbH
eTheRNA immunotherapies
Nutcracker Therapeutics
ReCode Therapeutics
Ziphius Vaccines
Sana Biotechnology
Beam Therapeutics
CRISPR Therapeutics
Intellia Therapeutics
Omega Therapeutics
Entos Pharmaceuticals
Arbutus Biopharma
Acuitas Therapeutics
Evox Therapeutics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Moderna's mRNA RSV Vaccine Secures FDA Approval
Moderna's mRNA-1345 vaccine, targeting Respiratory Syncytial Virus (RSV), received FDA approval for older adults. This marks a significant expansion of mRNA technology into established infectious disease markets beyond COVID-19, validating its broad applicability.
BioNTech Reports Positive Early Data for mRNA Cancer Vaccine Candidates
BioNTech announced encouraging initial clinical data for several personalized mRNA cancer vaccine candidates, including in pancreatic cancer. These developments highlight the platform's therapeutic potential for difficult-to-treat cancers, driving mRNA into oncology applications.
Pfizer Commits to Expanding mRNA Technology Beyond COVID-19 with New Pipeline Focus
Pfizer unveiled plans to significantly broaden its mRNA vaccine pipeline, investing in candidates for influenza, shingles, and other infectious diseases. This strategic move reinforces the long-term commitment of a major pharmaceutical player to the versatility and potential of mRNA platforms.
CureVac and GSK Advance Next-Generation mRNA Flu Vaccines to Phase 3 Trials
CureVac and GSK announced the progression of their modified mRNA seasonal influenza vaccine candidates into Phase 3 clinical trials. This milestone showcases the ongoing evolution of mRNA vaccines for established infectious diseases, aiming for improved efficacy and broader protection.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $18.8 Bn |
| Market Size (Forecast) | $62.7 Bn |
| CAGR | 12.8% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 27 Countries |
| Segments Covered | 6 Segments, 41 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the mRNA Therapeutics Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The mRNA Therapeutics Market is estimated at $18.8 Bn in 2025. It is projected to expand significantly, reflecting ongoing advancements and increasing adoption of mRNA-based medical solutions across various therapeutic areas globally.
The mRNA Therapeutics Market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 12.8% from 2025 to 2035. This growth rate indicates a strong upward trend driven by innovation and expanding applications.
The main segments include Prophylactic Mrna Vaccines, Therapeutic Mrna Vaccines, Mrna Therapies for Protein Replacement, Mrna Therapies for Gene Editing, Mrna Therapies for Regenerative Medicine, and Mrna Immunomodulators by Type. Other key segments cover Technology, Application, End-User, Component, and Process.
Leading companies in the mRNA Therapeutics Market include BioNTech, CureVac, Arcturus Therapeutics, Gritstone Bio, Orna Therapeutics, Strand Therapeutics, Ethris GmbH, eTheRNA immunotherapies, Nutcracker Therapeutics, ReCode Therapeutics, Ziphius Vaccines, and Sana Biotechnology. These companies are actively involved in research, development, and commercialization.
The mRNA Therapeutics market report covers a detailed analysis of market size, growth drivers, restraints, and opportunities. It includes segmentation by Type, Technology, Application, End-User, Component, and Process, along with regional analysis and profiles of leading companies, providing a comprehensive industry overview.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Alzheimer's Disease Therapeutics Market
$8.6 Bn in 2025 · 11.9% CAGR
Atopic Dermatitis Therapeutics Market
$18.7 Bn in 2025 · 8.4% CAGR
Autoimmune Disease Therapeutics Market
$168.0 Bn in 2025 · 6.1% CAGR
Computational Therapeutics Market
$600.0 Mn in 2025 · 18.6% CAGR
Epilepsy Therapeutics Market
$5.8 Bn in 2025 · 7.7% CAGR
Exosome Therapeutics Market
$186.1 Mn in 2025 · 28.6% CAGR
Inflammatory Bowel Disease Therapeutics Market
$27.6 Bn in 2025 · 5.2% CAGR
Longevity Therapeutics Market
$872.0 Mn in 2025 · 22.1% CAGR